386O Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC)

Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, Kensei Yamaguchi, Tomohiro Nishina, Elena Élez, J. Rodríguez, Ian Chau, Maria Di Bartolomeo, Hisato Kawakami, Fumitaka Suto, Kojiro Kobayashi, M Koga, Koichiro Inaki, Yusuke Kuwahara, Issey Takehara, Axel Grothey, Takayuki Yoshino